Market Update

The Wall Street Wrap: October 22, 2026
Market Update

The Wall Street Wrap: October 22, 2026

US stocks tumbled on Thursday as AI spending fears hit Meta, chipmakers, and power stocks, sending the Nasdaq Composite down 2.60% in its worst day since June, while consumer staples and utilities led and the Dow edged up 0.02%. Brent settled above $113 on Iran strike reports, and after hours Deckers, SS&C, and Comfort Systems fell while Omnicom, Newmont, and Western Digital rose. In Asia, the Nikkei and Kospi dropped as technology shares sold off.

Wall Street Wrap: Pre-Market, October 22, 2026
Pre Market

Wall Street Wrap: Pre-Market, October 22, 2026

U.S. stock futures slide on Thursday as Tesla and Meta disappoint, Lam Research and IBM sink, and AI-spending worries hit chip and neocloud stocks, while oil tops $111 on reports of fresh Iran strike plans and French yields top U.S. yields.

Big Tech Spends, Chipmakers Earn: Meta (NASDAQ:META), Tesla (NASDAQ:TSLA), Lam Research (NASDAQ:LRCX) and Other AI-Linked Tech Earnings
Earnings

Big Tech Spends, Chipmakers Earn: Meta (NASDAQ:META), Tesla (NASDAQ:TSLA), Lam Research (NASDAQ:LRCX) and Other AI-Linked Tech Earnings

Everyone is spending on AI. Meta, Lam Research, Texas Instruments, IBM and Tesla just showed who is turning it into cash, and who is still waiting.

The Debt Story Behind Getty Images: Record Revenue, Then Bankruptcy
Technology

The Debt Story Behind Getty Images: Record Revenue, Then Bankruptcy

Getty booked record revenue, then filed for bankruptcy. The real reason is not the one you think. Here’s the debt trail that brought the photo giant down.

The Wall Street Wrap: October 21, 2026
Market Update

The Wall Street Wrap: October 21, 2026

US stocks rose on Wednesday as SpaceX's results revived the AI trade, lifting the Nasdaq Composite 1.05% and information technology 1.61%, while AT&T and Netflix sank. Meta's $25 billion New Mexico penalty and a brief spike in France's 10-year yield above 5% added to the day's headlines, and after hours Meta, IBM, and QuantumScape rose while Lam Research and Graco fell. Abroad, South Korea's Kospi jumped 3.29%.

Wall Street Wrap: Pre-Market, October 21, 2026
Pre Market

Wall Street Wrap: Pre-Market, October 21, 2026

U.S. stock futures rise on Wednesday as SpaceX surges on blowout earnings and Tesla merger talks, and Super Micro jumps on a surprise guidance lift, while Netflix and AT&T slide and Alpha Teknova plunges on a stock offering.

The Wall Street Wrap: October 20, 2026
Market Update

The Wall Street Wrap: October 20, 2026

US stocks rose on Tuesday as upbeat earnings and falling oil prices lifted the Dow 1.02% and nine of 11 sectors, even as the Nasdaq Composite slipped 0.02% and information technology fell 0.34%. Housing data showed a deep freeze, with pending home sales down 7.3%, and after hours SpaceX and Capital One rose on results while Netflix and Intuitive Surgical fell. Abroad, France prepared to deploy soldiers ahead of more protests and South Korea's Kospi fell 3.73%.

Eli Lilly to Sanofi: Why Six Healthcare Stocks Carry Such Different Valuations
Healthcare Stocks

Eli Lilly to Sanofi: Why Six Healthcare Stocks Carry Such Different Valuations

Healthcare touched record levels on Tuesday, yet the six stocks here were driven less by the sector than by dated events of their own: insurer earnings, litigation, restructuring and deals. DaVita fell almost 6% against the tide, while Myriad jumped 37% on an asset sale. The useful question is which valuation already allows for the risks the calendar is about to test.

Elevance to Myriad: Why Earnings Dates and Legal Risk Outweigh the Sector Tide
Healthcare Stocks

Elevance to Myriad: Why Earnings Dates and Legal Risk Outweigh the Sector Tide

Healthcare touched record levels on Tuesday, yet the six stocks here were driven less by the sector than by dated events of their own: insurer earnings, litigation, restructuring and deals. DaVita fell almost 6% against the tide, while Myriad jumped 37% on an asset sale. The useful question is which valuation already allows for the risks the calendar is about to test.

Biotech Stocks Before ESMO: When Does Good Clinical Data Move the Price?
Healthcare Stocks

Biotech Stocks Before ESMO: When Does Good Clinical Data Move the Price?

Positive trial results do not always lift a share price, and a rising share price does not always rest on good news. Six biotech stocks, from Moderna to Zenas, are judged by three tests: how much is already priced in, how long the cash lasts, and what catalyst comes next. With the ESMO congress opening on October 23 and Treasury yields near 5.1%, the bar for good data is high.